Center for Drug Evaluation and Research growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split. In its original form, CDER was composed of six offices: Management, Compliance, Drug Standards, Drug Evaluation I, Drug Evaluation II, Epidemiology and Biostatistics, and Research Resources. The Division of Antiviral Products was added in 1989 under Drug Evaluation II due to the large amount of drugs proposed for treating AIDS. The Office of Generic Drugs was also formed. In 2002,
Drug Trafficking Safe Harbor Elimination Act are the five scheduled categories: 1. A Schedule I drug is listed as a substance that has a high risk for abuse and is not accepted as safe or for treatment by the medical community. According to the DEA List of Scheduled Substances, examples of a Schedule I Drug are: heroin, lysergic acid diethylamide (LSD), marijuana, peyote, and methylenedioxymethamphetamine. 2. A Schedule II drug is listed as another drug for high abuse risk. This scheduled drug has been used for medical treatment under medical supervision, but can lead to dependency or mental health issues. According to the DEA List of